SEHK:2616Biotechs
Is CStone Pharmaceuticals (SEHK:2616) Fully Valued On Interim Results And CS2009 Progress?
CStone Pharmaceuticals (SEHK:2616) stock is in focus after the company released its 2026 interim update, highlighting fresh CS2009 clinical data, stronger pralsetinib uptake, and progress toward global Phase III trials.
At a latest share price of HK$6.18, CStone Pharmaceuticals has seen a 1 month share price return of 42.07% and a 90 day share price return of 23.35%. However, the 1 year total shareholder return declined 48.93%, which hints that recent clinical and interim results have...